Ethanol

Alto Ingredients, Inc. Enters Letter of Intent with Vault to Advance Carbon Capture and Storage Initiative

Retrieved on: 
Monday, March 11, 2024
Vault, CCS, Employment, Letter, CO2, Ethanol, Carbon, Environment, Management

The letter of intent provides that Alto will install equipment to capture carbon dioxide (CO2) generated from the ethanol production process at its Pekin campus and Vault will safely transport and permanently store the emissions deep underground in a secure geologic reservoir located in close proximity to the campus.

Key Points: 
  • The letter of intent provides that Alto will install equipment to capture carbon dioxide (CO2) generated from the ethanol production process at its Pekin campus and Vault will safely transport and permanently store the emissions deep underground in a secure geologic reservoir located in close proximity to the campus.
  • The project is intended to substantially reduce CO2 emissions from the ethanol production process and provide direct value to the surrounding communities.
  • Both Alto and Vault continue to engage with local stakeholders, landowners, and communities regarding the project.
  • Alto Ingredients intends for the project to enable the Pekin campus to continue to contribute employment and economic opportunities for the local communities while substantially reducing atmospheric carbon dioxide.

Gevo Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Carbon, Engineering, Inflation, LG Chem, Depreciation, Research, Aviation, Renewable natural gas, LCFS, British thermal unit, Investment, Farmer, Growth, Sale, GEVO, SAF, GAAP, Interest, Plastic, Department of the Treasury, Agriculture, Treasury, Workforce, USDA, Ethanol, RNG, Cryptocurrency

ENGLEWOOD, Colo., March 07, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the fourth quarter and full year 2023 and recent corporate highlights.

Key Points: 
  • ENGLEWOOD, Colo., March 07, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the fourth quarter and full year 2023 and recent corporate highlights.
  • Net-Zero 1 and 2024 Expected Uses of Cash: We ended the fourth quarter with cash, cash equivalents, and restricted cash of $375.6 million.
  • Verity: In the third quarter of 2023, our Verity Tracking platform went live with farmers in South Dakota and Minnesota.
  • Gevo NW Iowa RNG generated positive, stand-alone non-GAAP cash EBITDA1 of $1.3 million for the fourth quarter.

Aemetis Reports 2023 Fourth Quarter and Year-End Results

Retrieved on: 
Thursday, March 7, 2024
Engineering, Collection, Operating cost, The Twelve Months, Ethanol, Aviation, Renewable natural gas, Natural gas, Growth, Sale, CEQA, Authority, Adjustment, Carbon, D3, Construct, CO2, Public expenditure, Acceleration, IRA, Three Months, Investment, USDA, Video game

CUPERTINO, CA, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and twelve months ended December 31, 2023.

Key Points: 
  • “Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • Financial Results for the Three Months Ended December 31, 2023
    Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • The ethanol gallons sold increased from 13.4 million gallons during the fourth quarter of 2022 to 15 million gallons during the fourth quarter of 2023.
  • Selling, general and administrative expenses rose from $7.5 million during the fourth quarter of 2022 to $9.8 million during the fourth quarter of 2023.

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Wednesday, March 6, 2024
Nervous system, POC, AMIX, Collateral damage, Quality of life, Pain, Patient, Clinical trial, Disease, Pancreatic cancer, Ethanol, Medical imaging

THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has commenced patient enrollment for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to commence enrollment of the PoC human clinical trial and take another step toward validating our clinical and regulatory plans for our technology,” commented Lori Bisson, Chief Executive Officer of Autonomix.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.
  • Confirmation of suitability will be affirmed by the primary oncology service caring for the patients.
  • Up to 5 additional patients will be included and treated according to protocol to ensure the physician’s familiarity with the procedure.

Stellantis Announces €5.6 Billion Investment in South America, Marking the Largest Investment in the Region’s Automotive Industry

Retrieved on: 
Wednesday, March 6, 2024
Engineering, Dare, BEV, Investment, Fiat, Carbon, History, Fiat Strada, Ethanol, Renewable energy

“This announcement solidifies our trust and commitment in the future of the South American automotive industry and is a response to the favorable business environment here,” said Stellantis CEO Carlos Tavares.

Key Points: 
  • “This announcement solidifies our trust and commitment in the future of the South American automotive industry and is a response to the favorable business environment here,” said Stellantis CEO Carlos Tavares.
  • The Stellantis facility in Betim, Brazil is the Company’s global center of expertise for Bio-Hybrid technology, continuing its legacy of innovation.
  • Stellantis is the leader in the three main markets in South America: Brazil, Argentina, and Chile.
  • With this investment, Stellantis will be increasingly prepared to design, develop, and produce modern cars in the region, while also expanding its business.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024
Nervous system, MEDLINE, POC, AMIX, Collateral damage, Pain, ChromeOS, Patient, Clinical trial, SIV, Disease, Naval ship, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

LanzaTech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Outlook

Retrieved on: 
Wednesday, February 28, 2024
Engineering, Quarter, IPA, Research, Investment, Aviation, MEG, Work, Growth, Suncor Energy, Propylene glycol, Chairperson, Carbon, Aviation biofuel, JDA, Safety, Workforce, Fermentation, PET, Ethanol, Video game

CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today reported its financial and operating results for the fourth quarter and full year 2023.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    In the fourth quarter of 2023, revenue totaled $20.5 million, reflecting an increase of 77% compared to $11.6 million in the fourth quarter of 2022.
  • Gross margin improved to 41% during the fourth quarter, reflecting certain engineering services work completed during the quarter which benefited from extraordinary pricing terms.
  • “However, our results for the fourth quarter and full year 2023 demonstrate we have a lot more work ahead of us.
  • Cash burn during the fourth quarter 2023 was $(15.4) million, continuing the trend over 2023 of reducing quarterly cash burn.

Agrify Corporation Announces Pricing of $2.6 Million Public Offering

Retrieved on: 
Wednesday, February 28, 2024
Attention, Prospectus, Burns, ROI, Sale, Equity capital markets, Form, Public expenditure, Science, Ethanol, Security (finance)

TROY, Mich., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the pricing of its public offering of 6,723,684 shares of common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.38 per share.

Key Points: 
  • TROY, Mich., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the pricing of its public offering of 6,723,684 shares of common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.38 per share.
  • Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $2.6 million.
  • The offering is expected to close on February 28, 2024, subject to customary closing conditions.
  • The securities described above are being offered by Agrify pursuant to a registration statement on Form S-1, as amended (File No.

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Retrieved on: 
Thursday, February 22, 2024
Nervous system, POC, AMIX, Principal, Collateral damage, Pain, Principal investigator, Patient, Disease, Trial of the century, Ethanol, Medical imaging

THE WOODLANDS, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study.

Key Points: 
  • Additionally, the Principal Investigators have successfully completed training for the PoC study.
  • “We are building important momentum with the advancement of our PoC human clinical study.
  • We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

Aemetis Announces Updated Five Year Plan Projecting Growth to $1.95 Billion of Revenue and $645 Million of Adjusted EBITDA in 2028

Retrieved on: 
Tuesday, February 20, 2024
Carbon, Engineering, Inflation, AI, Ethanol, Aviation, LCFS, Natural gas, Growth, Sale, CEQA, Oil, CCUS, CO2, Mechanical vapor recompression, Electricity, EPA, IRA, MVR, USDA, RNG, Renewable energy

The 2024 Plan states revenues are expected to grow at a compound annual growth rate of 38%, and adjusted EBITDA is expected to grow at a projected compound annual growth rate of 83% for the years 2024 to 2028.

Key Points: 
  • The 2024 Plan states revenues are expected to grow at a compound annual growth rate of 38%, and adjusted EBITDA is expected to grow at a projected compound annual growth rate of 83% for the years 2024 to 2028.
  • The presentation also describes the tax credits expected to be received by Aemetis from the Inflation Reduction Act (IRA) for its renewable fuel and sequestration projects.
  • “Additionally, Aemetis closed $50 million of new USDA funding and received $55 million from the sale of IRA tax credits in the past year.
  • The Five Year Plan for Aemetis Dairy RNG operations projects revenues will grow from $18 million in 2024 to $190 million in 2028, while Dairy RNG project EBITDA is expected to expand from $7 million in 2024 to $123 million in 2028.